Phase 4
Completed N=36
Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients
Source: ClinicalTrials.gov NCT00123643 ↗Enrolled (actual)
36
Serious AEs
0.0%
Results posted
Aug 2012
Primary outcomePrimary: Flow Mediated Dilation — 6.8; 5.5 percent change
Summary
The purpose of this study is to compare the vascular effects of two commonly used diabetes medications, rosiglitazone and glyburide in type 2 diabetic patients.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Flow Mediated Dilation |
6.8; 5.5 | — |
Eligibility Criteria
Inclusion Criteria
- Age 25-75 years
- Type 2 diabetes mellitus for less than or equal to 10 years
- Pre-screening HbA1c > 6.5 %
- Screening 110 mg/dl 160 mmol/l
- Anemia (Hb 42 kg/m2
- History of ketoacidosis
- Angina/New York Health Academy class III/IV cardiac insufficiency
- Electrocardiographic evidence of marked left ventricular hypertrophy
- Uncontrolled hypertension according to AHA guidelines
- Hemoglobinopathy
Data sourced from ClinicalTrials.gov (NCT00123643). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.